RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

Oncogenic activation of fibroblast growth factor receptor 2 (FGFR2) drives multiple cancers and represents a broad therapeutic opportunity, yet selective targeting of FGFR2 has not been achieved. Although the clinical efficacy of pan-FGFR inhibitors (pan-FGFRi) validates FGFR2 driver status in FGFR2...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Sahai, Vaibhav, Maglic, Dejan, Bruderek, Kamil, Touré, B. Barry, Zhao, Songping, Valverde, Roberto, O'Hearn, Patrick J., Moustakas, Demetri T., Schönherr, Heike, Gerami-Moayed, Nastaran, Taylor, Alexander M., Hudson, Brandi M., Houde, Damian J., Pal, Debjani, Foster, Lindsey, Gunaydin, Hakan, Ayaz, Pelin, Sharon, Dina A., Goyal, Lipika, Schram, Alison M., Kamath, Suneel, Sherwin, Cori Ann, Schmidt-Kittler, Oleg, Jen, Kai Yu, Ricard, Fabien, Wolf, Beni B., Shaw, David E., Bergstrom, Donald A., Watters, James, Casaletto, Jessica B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481131/
https://www.ncbi.nlm.nih.gov/pubmed/37270847
http://dx.doi.org/10.1158/2159-8290.CD-23-0475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481131/
https://www.ncbi.nlm.nih.gov/pubmed/37270847
http://dx.doi.org/10.1158/2159-8290.CD-23-0475

Ejemplares similares